skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Suppression of atherosclerosis by synthetic REV-ERB agonist

Abstract

The nuclear receptors for heme, REV-ERBα and REV-ERBβ, play important roles in the regulation of metabolism and inflammation. Recently it was demonstrated that reduced REV-ERBα expression in hematopoetic cells in LDL receptor null mice led to increased atherosclerosis. We sought to determine if synthetic REV-ERB agonists that we have developed might have the ability to suppress atherosclerosis in this model. A previously characterized synthetic REV-ERB agonist, SR9009, was used to determine if activation of REV-ERB activity would affect atherosclerosis in LDL receptor deficient mice. Atherosclerotic plaque size was significantly reduced (p < 0.05) in mice administered SR9009 (100 mg/kg) for seven weeks compared to control mice (n = 10 per group). SR9009 treatment of bone marrow-derived mouse macrophages (BMDM) reduced the polarization of BMDMs to proinflammatory M1 macrophage while increasing the polarization of BMDMs to anti-inflammatory M2 macrophages. Our results suggest that pharmacological targeting of REV-ERBs may be a viable therapeutic option for treatment of atherosclerosis. - Highlights: • Synthetic REV-ERB agonist treatment reduced atherosclerosis in a mouse model. • Pharmacological activation of REV-ERB decreased M1 macrophage polarization. • Pharmacological activation of REV-ERB increased M2 macrophage polarization.

Authors:
 [1];  [2]; ;  [1];  [2]
  1. Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL 33458 (United States)
  2. Department of Pharmacological & Physiological Science, Saint Louis University School of Medicine, St. Louis, MO 63104 (United States)
Publication Date:
OSTI Identifier:
22462033
Resource Type:
Journal Article
Journal Name:
Biochemical and Biophysical Research Communications
Additional Journal Information:
Journal Volume: 460; Journal Issue: 3; Other Information: Copyright (c) 2015 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0006-291X
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; ARTERIOSCLEROSIS; BONE MARROW; COMPARATIVE EVALUATIONS; CONTROL; HEME; INFLAMMATION; INHIBITION; MACROPHAGES; METABOLISM; MICE; POLARIZATION; RECEPTORS

Citation Formats

Sitaula, Sadichha, Billon, Cyrielle, Kamenecka, Theodore M., Solt, Laura A., and Burris, Thomas P., E-mail: burristp@slu.edu. Suppression of atherosclerosis by synthetic REV-ERB agonist. United States: N. p., 2015. Web. doi:10.1016/J.BBRC.2015.03.070.
Sitaula, Sadichha, Billon, Cyrielle, Kamenecka, Theodore M., Solt, Laura A., & Burris, Thomas P., E-mail: burristp@slu.edu. Suppression of atherosclerosis by synthetic REV-ERB agonist. United States. doi:10.1016/J.BBRC.2015.03.070.
Sitaula, Sadichha, Billon, Cyrielle, Kamenecka, Theodore M., Solt, Laura A., and Burris, Thomas P., E-mail: burristp@slu.edu. Fri . "Suppression of atherosclerosis by synthetic REV-ERB agonist". United States. doi:10.1016/J.BBRC.2015.03.070.
@article{osti_22462033,
title = {Suppression of atherosclerosis by synthetic REV-ERB agonist},
author = {Sitaula, Sadichha and Billon, Cyrielle and Kamenecka, Theodore M. and Solt, Laura A. and Burris, Thomas P., E-mail: burristp@slu.edu},
abstractNote = {The nuclear receptors for heme, REV-ERBα and REV-ERBβ, play important roles in the regulation of metabolism and inflammation. Recently it was demonstrated that reduced REV-ERBα expression in hematopoetic cells in LDL receptor null mice led to increased atherosclerosis. We sought to determine if synthetic REV-ERB agonists that we have developed might have the ability to suppress atherosclerosis in this model. A previously characterized synthetic REV-ERB agonist, SR9009, was used to determine if activation of REV-ERB activity would affect atherosclerosis in LDL receptor deficient mice. Atherosclerotic plaque size was significantly reduced (p < 0.05) in mice administered SR9009 (100 mg/kg) for seven weeks compared to control mice (n = 10 per group). SR9009 treatment of bone marrow-derived mouse macrophages (BMDM) reduced the polarization of BMDMs to proinflammatory M1 macrophage while increasing the polarization of BMDMs to anti-inflammatory M2 macrophages. Our results suggest that pharmacological targeting of REV-ERBs may be a viable therapeutic option for treatment of atherosclerosis. - Highlights: • Synthetic REV-ERB agonist treatment reduced atherosclerosis in a mouse model. • Pharmacological activation of REV-ERB decreased M1 macrophage polarization. • Pharmacological activation of REV-ERB increased M2 macrophage polarization.},
doi = {10.1016/J.BBRC.2015.03.070},
journal = {Biochemical and Biophysical Research Communications},
issn = {0006-291X},
number = 3,
volume = 460,
place = {United States},
year = {2015},
month = {5}
}